Here are the 424B prospectus supplements from ADARx Pharmaceuticals, Inc. (ADRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ADRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADRX filings page.
ADARx Pharmaceuticals, Inc. (ADRX) is offering 26,250,000 shares of common stock in its IPO at $17.00 per share. The company lists proceeds of $415,012,500 before expenses. Underwriters may buy up to 3,937,500 additional shares during a 30-day option. Separately, AbbVie agreed to buy 5,233,264 shares in a concurrent private placement, contingent on the IPO closing; the purchase is capped at $100.0 million and would give AbbVie approximately 4.9% of post-closing shares.
ADARx develops siRNA medicines, with three clinical-stage and two advanced preclinical programs. For the six months ended June 30, 2026, collaboration revenue was $2.886 million, compared with $208,000 in 2025, while net loss was $48.426 million versus $33.644 million. Cash, cash equivalents and short-term investments totaled $427.252 million as of June 30, 2026. Based on current operating plans, ADARx says net proceeds from this offering and the private placement, together with existing cash, are expected to fund projected operating expenses and capital expenditure requirements into 2030.